Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial

Edward S. Friedman, Lori L. Davis, Sidney Zisook, Stephen R. Wisniewski, Madhukar H. Trivedi, Maurizio Fava, A. John Rush

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The objective of this manuscript is to report associations between baseline depressive severity and (1) baseline sociodemographic and clinical characteristics, (2) treatment outcomes, and (3) differential outcomes for three treatment groups. Six hundred and sixty-five outpatients with nonpsychotic, major depressive disorder were prospectively randomized to treatment with either a selective serotonin reuptake inhibitor (SSRI) monotherapy (escitalopram plus placebo) or one of two antidepressant medication combinations (bupropion-sustained release plus escitalopram, or venlafaxine-extended release plus mirtazapine). For purposes of these analyses, participants were divided into four groups based on baseline severity by the 16-item Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR 16) total score: mild (0-10) [N=81], moderate (11-15) [N=238], severe (16-20) [N=260] and very severe (21-27) [N=67]. Treatment outcomes at 12 and 28weeks were compared among the four severity groups. A history of childhood neglect and/or abuse was strongly associated with the severity of adult depression (1/2 of participants in the very severe group versus 1/5-1/4 of those in the mild group reported abuse and/or neglect). The degree of suicidality (e.g., 15/.4% of the very severe group ever attempted suicide versus none in the mild group), the number of suicide attempts (e.g., mean of .41±1.99 suicide attempts in the severe group versus 0.0±0.0 in the mild group) and severity of suicidality (e.g., 9.2% of participants in very severe group had a plan or made a gesture versus 5.6% in moderate group and none in the mild group) were increased in more severe groups. Participants with a greater baseline depressive severity reported significantly more psychiatric comorbidities (e.g. [at p<.05] increased rates of agoraphobia, bulimia, generalized anxiety, hypocondriasis, panic disorder, post-traumatic stress disorder, social phobia and somatoform disorder, with 23.9% of participants in the very severe group having reported four or more psychiatric disorders versus 1.2% of the mild group). Combination medication treatments were no more effective in treating severe depressions than was SSRI monotherapy. Remission (61.7% of participants in the mild group achieved remission versus 28.4% in the very severe group) is more difficult to achieve in more severe groups than is response (48.8% of participants in the mild group achieved response versus 58.2% in the very severe group) (p<.03). These data may help us to understand the impact of baseline features on antidepressant medication effectiveness and to inform the personalization of depression treatment across the spectrum of depressive severity.

Original languageEnglish (US)
Pages (from-to)183-199
Number of pages17
JournalEuropean Neuropsychopharmacology
Volume22
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Carbon Monoxide
Antidepressive Agents
Citalopram
Serotonin Uptake Inhibitors
Depression
Suicide
Psychiatry
Agoraphobia
Bupropion
Attempted Suicide
Gestures
Bulimia
Somatoform Disorders
Panic Disorder
Major Depressive Disorder
Post-Traumatic Stress Disorders
Self Report
Comorbidity
Outpatients
Anxiety

Keywords

  • Abuse
  • Combination treatment severity
  • Depression
  • Remission
  • Response
  • Suicide

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Biological Psychiatry
  • Neurology
  • Pharmacology

Cite this

Baseline depression severity as a predictor of single and combination antidepressant treatment outcome : Results from the CO-MED trial. / Friedman, Edward S.; Davis, Lori L.; Zisook, Sidney; Wisniewski, Stephen R.; Trivedi, Madhukar H.; Fava, Maurizio; Rush, A. John.

In: European Neuropsychopharmacology, Vol. 22, No. 3, 03.2012, p. 183-199.

Research output: Contribution to journalArticle

Friedman, Edward S. ; Davis, Lori L. ; Zisook, Sidney ; Wisniewski, Stephen R. ; Trivedi, Madhukar H. ; Fava, Maurizio ; Rush, A. John. / Baseline depression severity as a predictor of single and combination antidepressant treatment outcome : Results from the CO-MED trial. In: European Neuropsychopharmacology. 2012 ; Vol. 22, No. 3. pp. 183-199.
@article{23a9946a71334616ba48fab6b188e113,
title = "Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial",
abstract = "The objective of this manuscript is to report associations between baseline depressive severity and (1) baseline sociodemographic and clinical characteristics, (2) treatment outcomes, and (3) differential outcomes for three treatment groups. Six hundred and sixty-five outpatients with nonpsychotic, major depressive disorder were prospectively randomized to treatment with either a selective serotonin reuptake inhibitor (SSRI) monotherapy (escitalopram plus placebo) or one of two antidepressant medication combinations (bupropion-sustained release plus escitalopram, or venlafaxine-extended release plus mirtazapine). For purposes of these analyses, participants were divided into four groups based on baseline severity by the 16-item Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR 16) total score: mild (0-10) [N=81], moderate (11-15) [N=238], severe (16-20) [N=260] and very severe (21-27) [N=67]. Treatment outcomes at 12 and 28weeks were compared among the four severity groups. A history of childhood neglect and/or abuse was strongly associated with the severity of adult depression (1/2 of participants in the very severe group versus 1/5-1/4 of those in the mild group reported abuse and/or neglect). The degree of suicidality (e.g., 15/.4{\%} of the very severe group ever attempted suicide versus none in the mild group), the number of suicide attempts (e.g., mean of .41±1.99 suicide attempts in the severe group versus 0.0±0.0 in the mild group) and severity of suicidality (e.g., 9.2{\%} of participants in very severe group had a plan or made a gesture versus 5.6{\%} in moderate group and none in the mild group) were increased in more severe groups. Participants with a greater baseline depressive severity reported significantly more psychiatric comorbidities (e.g. [at p<.05] increased rates of agoraphobia, bulimia, generalized anxiety, hypocondriasis, panic disorder, post-traumatic stress disorder, social phobia and somatoform disorder, with 23.9{\%} of participants in the very severe group having reported four or more psychiatric disorders versus 1.2{\%} of the mild group). Combination medication treatments were no more effective in treating severe depressions than was SSRI monotherapy. Remission (61.7{\%} of participants in the mild group achieved remission versus 28.4{\%} in the very severe group) is more difficult to achieve in more severe groups than is response (48.8{\%} of participants in the mild group achieved response versus 58.2{\%} in the very severe group) (p<.03). These data may help us to understand the impact of baseline features on antidepressant medication effectiveness and to inform the personalization of depression treatment across the spectrum of depressive severity.",
keywords = "Abuse, Combination treatment severity, Depression, Remission, Response, Suicide",
author = "Friedman, {Edward S.} and Davis, {Lori L.} and Sidney Zisook and Wisniewski, {Stephen R.} and Trivedi, {Madhukar H.} and Maurizio Fava and Rush, {A. John}",
year = "2012",
month = "3",
doi = "10.1016/j.euroneuro.2011.07.010",
language = "English (US)",
volume = "22",
pages = "183--199",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Baseline depression severity as a predictor of single and combination antidepressant treatment outcome

T2 - Results from the CO-MED trial

AU - Friedman, Edward S.

AU - Davis, Lori L.

AU - Zisook, Sidney

AU - Wisniewski, Stephen R.

AU - Trivedi, Madhukar H.

AU - Fava, Maurizio

AU - Rush, A. John

PY - 2012/3

Y1 - 2012/3

N2 - The objective of this manuscript is to report associations between baseline depressive severity and (1) baseline sociodemographic and clinical characteristics, (2) treatment outcomes, and (3) differential outcomes for three treatment groups. Six hundred and sixty-five outpatients with nonpsychotic, major depressive disorder were prospectively randomized to treatment with either a selective serotonin reuptake inhibitor (SSRI) monotherapy (escitalopram plus placebo) or one of two antidepressant medication combinations (bupropion-sustained release plus escitalopram, or venlafaxine-extended release plus mirtazapine). For purposes of these analyses, participants were divided into four groups based on baseline severity by the 16-item Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR 16) total score: mild (0-10) [N=81], moderate (11-15) [N=238], severe (16-20) [N=260] and very severe (21-27) [N=67]. Treatment outcomes at 12 and 28weeks were compared among the four severity groups. A history of childhood neglect and/or abuse was strongly associated with the severity of adult depression (1/2 of participants in the very severe group versus 1/5-1/4 of those in the mild group reported abuse and/or neglect). The degree of suicidality (e.g., 15/.4% of the very severe group ever attempted suicide versus none in the mild group), the number of suicide attempts (e.g., mean of .41±1.99 suicide attempts in the severe group versus 0.0±0.0 in the mild group) and severity of suicidality (e.g., 9.2% of participants in very severe group had a plan or made a gesture versus 5.6% in moderate group and none in the mild group) were increased in more severe groups. Participants with a greater baseline depressive severity reported significantly more psychiatric comorbidities (e.g. [at p<.05] increased rates of agoraphobia, bulimia, generalized anxiety, hypocondriasis, panic disorder, post-traumatic stress disorder, social phobia and somatoform disorder, with 23.9% of participants in the very severe group having reported four or more psychiatric disorders versus 1.2% of the mild group). Combination medication treatments were no more effective in treating severe depressions than was SSRI monotherapy. Remission (61.7% of participants in the mild group achieved remission versus 28.4% in the very severe group) is more difficult to achieve in more severe groups than is response (48.8% of participants in the mild group achieved response versus 58.2% in the very severe group) (p<.03). These data may help us to understand the impact of baseline features on antidepressant medication effectiveness and to inform the personalization of depression treatment across the spectrum of depressive severity.

AB - The objective of this manuscript is to report associations between baseline depressive severity and (1) baseline sociodemographic and clinical characteristics, (2) treatment outcomes, and (3) differential outcomes for three treatment groups. Six hundred and sixty-five outpatients with nonpsychotic, major depressive disorder were prospectively randomized to treatment with either a selective serotonin reuptake inhibitor (SSRI) monotherapy (escitalopram plus placebo) or one of two antidepressant medication combinations (bupropion-sustained release plus escitalopram, or venlafaxine-extended release plus mirtazapine). For purposes of these analyses, participants were divided into four groups based on baseline severity by the 16-item Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR 16) total score: mild (0-10) [N=81], moderate (11-15) [N=238], severe (16-20) [N=260] and very severe (21-27) [N=67]. Treatment outcomes at 12 and 28weeks were compared among the four severity groups. A history of childhood neglect and/or abuse was strongly associated with the severity of adult depression (1/2 of participants in the very severe group versus 1/5-1/4 of those in the mild group reported abuse and/or neglect). The degree of suicidality (e.g., 15/.4% of the very severe group ever attempted suicide versus none in the mild group), the number of suicide attempts (e.g., mean of .41±1.99 suicide attempts in the severe group versus 0.0±0.0 in the mild group) and severity of suicidality (e.g., 9.2% of participants in very severe group had a plan or made a gesture versus 5.6% in moderate group and none in the mild group) were increased in more severe groups. Participants with a greater baseline depressive severity reported significantly more psychiatric comorbidities (e.g. [at p<.05] increased rates of agoraphobia, bulimia, generalized anxiety, hypocondriasis, panic disorder, post-traumatic stress disorder, social phobia and somatoform disorder, with 23.9% of participants in the very severe group having reported four or more psychiatric disorders versus 1.2% of the mild group). Combination medication treatments were no more effective in treating severe depressions than was SSRI monotherapy. Remission (61.7% of participants in the mild group achieved remission versus 28.4% in the very severe group) is more difficult to achieve in more severe groups than is response (48.8% of participants in the mild group achieved response versus 58.2% in the very severe group) (p<.03). These data may help us to understand the impact of baseline features on antidepressant medication effectiveness and to inform the personalization of depression treatment across the spectrum of depressive severity.

KW - Abuse

KW - Combination treatment severity

KW - Depression

KW - Remission

KW - Response

KW - Suicide

UR - http://www.scopus.com/inward/record.url?scp=84856514022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856514022&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2011.07.010

DO - 10.1016/j.euroneuro.2011.07.010

M3 - Article

C2 - 21920711

AN - SCOPUS:84856514022

VL - 22

SP - 183

EP - 199

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 3

ER -